UltraGreen.ai Limited (ULG) told investors at the 22nd CITIC CLSA ASEAN Forum that FY2025 revenue increased 24 % year-on-year, driven by a 13 % rise in vials sold and a 17 % improvement in average selling prices. Gross margin remained at 85 %, while adjusted EBITDA margin edged up to 62.8 %.

Net profit before exceptional items rose 14 % year-on-year. After booking a gain on the disposal of its UltraLinQ unit, full-year net profit reached 75.6 million.

Following its December 2025 listing on Singapore Exchange, the company ended FY2025 in a net cash position and lifted total equity to 310.6 million.

Management guided for FY2026 revenue of 170 million to 190 million, representing anticipated growth of 19–33 %. The outlook is supported by wider geographic approvals—Verdye/IC-Green is now cleared in 40 countries—and expanded indications such as breast sentinel lymph-node mapping in Germany.

UltraGreen.ai said it now has two validated active-pharmaceutical-ingredient suppliers and annual indocyanine green capacity roughly double projected FY2026 demand, with the ability to scale further as adoption of fluorescence-guided surgery grows.